Delineating the Spectrum of Pituitary Adenoma Based on the WHO 2017 Classification.
Journal
Neurology India
ISSN: 1998-4022
Titre abrégé: Neurol India
Pays: India
ID NLM: 0042005
Informations de publication
Date de publication:
01 Jan 2024
01 Jan 2024
Historique:
received:
22
06
2020
accepted:
17
10
2020
medline:
6
3
2024
pubmed:
6
3
2024
entrez:
5
3
2024
Statut:
ppublish
Résumé
The WHO 2017 classification of endocrine tumors incorporates lineage-specific transcription factors (TF) and hormone expression for the classification of pituitary adenoma (PA). There is paucity of reports describing the spectrum of PA based on this classification. The aim of this study was to delineate the spectrum of PA based on WHO 2017 classification of endocrine tumors. PA diagnosed in the year 2018 were studied. H and E and hormonal immunohistochemistry (IHC) for GH, PRL, ACTH, TSH, FSH, LH, CK, T-Pit and MIB-1 were performed and the results were analyzed. The cohort included 88 cases. M: F ratio was 2:1. Clinically, 22 (25%) were functional and 66 (75%) were non-functional adenomas. Amongst the clinically functional adenomas, GH secreting adenomas were the commonest (68%). Majority (83%) of non-functional adenomas were hormone positive with gonadotroph adenomas being the commonest (72.7%). Eleven (12.5%) PA were clinically and hormonally silent. Three of these showed intense nuclear T-Pit positivity, classifying them under silent corticotroph adenoma. Lineage of the remaining eight adenomas remained undetermined, since, IHC for Pit-1 and SF-1 was not performed. The aggressive adenomas identified by IHC included sparsely granulated somatotroph adenoma, Crooke cell adenoma, silent corticotroph adenoma, densely granulated lactotroph adenoma in men and constituted 17% of the PA. Four (4/88) cases were clinically invasive. A large majority of PA including aggressive adenomas can be identified by IHC. Addition of T-Pit helped to identify silent corticotroph adenoma. Pit -1 and SF-1 TF would help identify plurihormonal Pit-1 PA and null cell adenomas.
Sections du résumé
BACKGROUND
BACKGROUND
The WHO 2017 classification of endocrine tumors incorporates lineage-specific transcription factors (TF) and hormone expression for the classification of pituitary adenoma (PA). There is paucity of reports describing the spectrum of PA based on this classification.
OBJECTIVE
OBJECTIVE
The aim of this study was to delineate the spectrum of PA based on WHO 2017 classification of endocrine tumors.
MATERIALS AND METHODS
METHODS
PA diagnosed in the year 2018 were studied. H and E and hormonal immunohistochemistry (IHC) for GH, PRL, ACTH, TSH, FSH, LH, CK, T-Pit and MIB-1 were performed and the results were analyzed.
RESULTS
RESULTS
The cohort included 88 cases. M: F ratio was 2:1. Clinically, 22 (25%) were functional and 66 (75%) were non-functional adenomas. Amongst the clinically functional adenomas, GH secreting adenomas were the commonest (68%). Majority (83%) of non-functional adenomas were hormone positive with gonadotroph adenomas being the commonest (72.7%). Eleven (12.5%) PA were clinically and hormonally silent. Three of these showed intense nuclear T-Pit positivity, classifying them under silent corticotroph adenoma. Lineage of the remaining eight adenomas remained undetermined, since, IHC for Pit-1 and SF-1 was not performed. The aggressive adenomas identified by IHC included sparsely granulated somatotroph adenoma, Crooke cell adenoma, silent corticotroph adenoma, densely granulated lactotroph adenoma in men and constituted 17% of the PA. Four (4/88) cases were clinically invasive.
CONCLUSION
CONCLUSIONS
A large majority of PA including aggressive adenomas can be identified by IHC. Addition of T-Pit helped to identify silent corticotroph adenoma. Pit -1 and SF-1 TF would help identify plurihormonal Pit-1 PA and null cell adenomas.
Identifiants
pubmed: 38443009
doi: 10.4103/neuroindia.NI_913_20
pii: 02223311-202472010-00019
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
96-101Informations de copyright
Copyright © 2024 Copyright: © 2024 Neurology India, Neurological Society of India.
Références
Lopes MB. The 2017 World Health Organization classification of tumors of the pituitary gland: A summary. Acta Neuropathol 2017;134:521–35
Zhu X, Gleiberman AS, Rosenfeld MG. Molecular physiology of pituitary development: Signaling and transcriptional networks. Physiol Rev 2007;87:933–63
Gupta T, Epari S, Moiyadi A, Shetty P, Goda JS, Krishnatry R, et al. Demographic profile, clinicopathological spectrum, and treatment outcomes of primary central nervous system tumors: Retrospective audit from an academic neuro-oncology unit. Indian J Cancer 2017;54:594–600
Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ME, et al. The prevalence of pituitary adenomas: A systematic review. Cancer 2004;101:613–9
Zerehpoosh FB, Sabeti S, Sharifi G, Shakeri H, Alipour S, Arman F. Demographic study of pituitary adenomas undergone trans-sphenoidal surgery in Loghman Hakim Hospital, Tehran, Iran, 2001-2013. Indian J Endocr Metab 2015;19:791–6
Trouillas J, Roy P, Sturm N, Dantony E, Rudelli CC, Viennet G, et al. A new prognostic clinicopathological classification of pituitary adenomas: A multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 2013;126:123–35
Felix IA, Rodriguez Mendoza L, Guinto G, Torres Corzo J, Wussterhaus CA. 120 biopsies of pituitary adenomas studied by immunohistochemistry and electron microscopy. A clinico-pathological correlation. Gac Med Mex 1992;128:289–95
Bhuyan M, Sarma D, Dutta D, Yadav Y, Das S. Clinicopathological study of pituitary adenomas in the region of northeast India. J Arab Soc Med Res 2016;11:43–9
Varlamov EV, McCartney S, Fleseriu M. Functioning pituitary adenomas-Current treatment options and emerging medical therapies. Eur Endocrinol 2019;15:3040
Mayr B, Buslei R, Theodoropoulou M, Stalla GK, Buchfelder M, Schofl C. Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas. Eur J Endocrinol 2013;169:391–400
Kato M, Inoshita N, Sugiyama T, Tani Y, Shichiri M, Sano T, et al. Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenoma. Endoc J 2012;59:221–8
Sathiyabama D, Asha U, Shwetha SD, Thakkar R, Dil JS, Santosh V. Crooke's cell adenoma of the pituitary: A histological, immunocytochemical, and electron microscopic study of a rare case. Neurol India 2014;62:216–7
Rishi A, Sharma MC, Sarkar C, Jain D, Singh M, Mahapatra AK, et al. A clinicopathological and immunohistochemical study of clinically non-functioning pituitary adenomas: A single institutional experience. Neurol India 2010;58:418–23
Jaffe CA. Clinically non-functioning pituitary adenoma. Pituitary 2006;9:317–21
Nishioka H, Inoshita N, Mete O, Asa SL, Hayashi K, Takeshita A, et al. The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas. Endocr Pathol 2015;26:349–55
Pawlikowski M, Kunert-Radek J, Radek M. Plurihormonality of pituitary adenomas in light of immunohistochemical studies. Pol J Endocrinol 2010;61:63–6
Mete O, Gomez-Hernandez K, Kucharczyk W, Ridout R, Zadeh G, Gentili F, et al. Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas. Modern Pathology 2016;29:131–42
Syro LV, Rotondo F, Camargo M, Ortiz LD, Serna CA, Kovacs K. Temozolomide and pituitary tumors: Current understanding, unresolved issues, and future directions. Front Endocrinol 2018;9:318
Moldovan IM, Melincovici C, Mihu CM, Susman S, Constantin AM, Florian SI. Diagnostic criteria in invasive pituitary adenomas. Romanian Neurosurgery 2016;30:342–55
Abe T, Sanno N, Osamura YR, Matsumoto K. Proliferative potential in pituitary adenomas: Measurement by monoclonal antibody MIB-1. Acta Neurochir 1997;139:613–8
Hadzhiyanev A, Ivanova R, Nachev E, Elenkova A, Yaneva M, Zaharieva S, et al. Evaluation of prognostic utility of MIB-1 and p53 expression in pituitary adenomas: Correlations with clinical behaviour and follow-up results. Biotechnol Biotechnol Equip 2014;28:502–7
Salehi F, Agur A, Scheithauer BW, Kovacs K, Lloyd RV, Cusimano M. Ki-67 in pituitary neoplasms: A review—part I. Neurosurgery 2009;65:429–37
Saeger W, Ludecke B, Ludecke DK. Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas. Exp Clin Endocrinol Diabetes 2008;116:80–5
Manojlovic-Gacic E, Engstrom BE, Casar-Borota O. Histopathological classification of non-functioning pituitary neuroendocrine tumors. Pituitary 2018;21:119–29
Salehi F, Scheithauer BW, Kros JM, Lau Q, Fealey M, Ericson D, et al. MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas. J Neurooncol 2011;104:647–57
Arya S, Majaid MA, Shwetha SD, Sravani K, Arivazhagan A, Sampath S, et al. Implications of MGMT methylation status in pituitary adenoma. Pathol Res Pract 2014;210:407–11
Drummond J, Roncaroli F, Grossman AB, Korbonits M. Clinical and pathological aspects of silent pituitary adenomas. J Clin Endocrinol Metab 2019;104:2473–89
Asa SL, Casar-Borota O, Chanson P, Delgrange E, Earls P, Ezzat S, et al. Pituitary adenoma to pituitary neuroendocrine tumor (PitNET): An international pituitary pathology club proposal. Endocr Relat Cancer 2017;24:C5–8